Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

Abstract Background The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients’ health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients’ HRQoL data, should have establish...

Full description

Bibliographic Details
Main Authors: Jeremiah J. Trudeau, Jianming He, Esther Rose, Charlotte Panter, Sharan Randhawa, Adam Gater
Format: Article
Language:English
Published: SpringerOpen 2020-08-01
Series:Journal of Patient-Reported Outcomes
Subjects:
Online Access:http://link.springer.com/article/10.1186/s41687-020-00235-4
id doaj-779326d4e0a64bd2a5b5ad52b1f0cdd3
record_format Article
spelling doaj-779326d4e0a64bd2a5b5ad52b1f0cdd32020-11-25T03:48:49ZengSpringerOpenJournal of Patient-Reported Outcomes2509-80202020-08-014111310.1186/s41687-020-00235-4Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromesJeremiah J. Trudeau0Jianming He1Esther Rose2Charlotte Panter3Sharan Randhawa4Adam Gater5Janssen Global Services LLCJanssen Global Services LLCJanssen Pharmaceuticals LLCAdelphi ValuesAdelphi ValuesAdelphi ValuesAbstract Background The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients’ health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients’ HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible. The present study was conducted to evaluate the content validity of the Quality of Life in Myelodysplasia Scale (QUALMS) and the Functional Assessment of Cancer Therapy-Anemia (FACT-An) PRO instruments in patients with lower-risk MDS. Methods In this cross-sectional, qualitative study, 16 patients aged ≥18 years with lower-risk MDS, who were RBC transfusion dependent, literate and fluent in US-English were interviewed. Interviews were semi-structured comprising of two parts: concept elicitation (CE) explored symptoms and impacts important to patients, and cognitive debriefing (CD) assessed understanding and relevance of the QUALMS and FACT-An. A conceptual model was developed, which was used to map the concepts that emerged during CE onto the QUALMS and FACT-An to assess concept coverage and suitability of the instruments. Results The median age of participants was 67.5 years (range: 51–91), with half being female (n = 8). Nine (56.2%) participants had intermediate-1-risk MDS and 10 (62.5%) were relapsed or refractory to erythropoiesis-stimulating agent treatment. Fatigue/tiredness (100.0%), shortness of breath (87.5%), weakness (81.2%), and low energy (75.0%) were reported most commonly and were the most bothersome symptoms as well. Of seven high-level HRQoL domains identified, activities of daily living (n = 16, 100.0%), physical functioning (n = 15, 93.8%), emotional wellbeing (n = 13, 81.3%), social functioning (n = 12, 75.0%), sleep disturbance (n = 9, 56.3%), and impact on work (n = 9, 56.3%) were the most commonly reported. For CD, the QUALMS and FACT-An were found to be mostly relevant and very well understood; response options were easy to use, and recall period was appropriate. Conclusion Both QUALMS and FACT-An demonstrated a strong face and content validity in patients with lower-risk MDS, suggesting that these instruments are appropriate for assessing HRQoL in this population.http://link.springer.com/article/10.1186/s41687-020-00235-4Myelodysplastic syndromePatient reported outcomesFACT-AnQUALMSHealth-related quality of life
collection DOAJ
language English
format Article
sources DOAJ
author Jeremiah J. Trudeau
Jianming He
Esther Rose
Charlotte Panter
Sharan Randhawa
Adam Gater
spellingShingle Jeremiah J. Trudeau
Jianming He
Esther Rose
Charlotte Panter
Sharan Randhawa
Adam Gater
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
Journal of Patient-Reported Outcomes
Myelodysplastic syndrome
Patient reported outcomes
FACT-An
QUALMS
Health-related quality of life
author_facet Jeremiah J. Trudeau
Jianming He
Esther Rose
Charlotte Panter
Sharan Randhawa
Adam Gater
author_sort Jeremiah J. Trudeau
title Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_short Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_full Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_fullStr Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_full_unstemmed Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_sort content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
publisher SpringerOpen
series Journal of Patient-Reported Outcomes
issn 2509-8020
publishDate 2020-08-01
description Abstract Background The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients’ health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients’ HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible. The present study was conducted to evaluate the content validity of the Quality of Life in Myelodysplasia Scale (QUALMS) and the Functional Assessment of Cancer Therapy-Anemia (FACT-An) PRO instruments in patients with lower-risk MDS. Methods In this cross-sectional, qualitative study, 16 patients aged ≥18 years with lower-risk MDS, who were RBC transfusion dependent, literate and fluent in US-English were interviewed. Interviews were semi-structured comprising of two parts: concept elicitation (CE) explored symptoms and impacts important to patients, and cognitive debriefing (CD) assessed understanding and relevance of the QUALMS and FACT-An. A conceptual model was developed, which was used to map the concepts that emerged during CE onto the QUALMS and FACT-An to assess concept coverage and suitability of the instruments. Results The median age of participants was 67.5 years (range: 51–91), with half being female (n = 8). Nine (56.2%) participants had intermediate-1-risk MDS and 10 (62.5%) were relapsed or refractory to erythropoiesis-stimulating agent treatment. Fatigue/tiredness (100.0%), shortness of breath (87.5%), weakness (81.2%), and low energy (75.0%) were reported most commonly and were the most bothersome symptoms as well. Of seven high-level HRQoL domains identified, activities of daily living (n = 16, 100.0%), physical functioning (n = 15, 93.8%), emotional wellbeing (n = 13, 81.3%), social functioning (n = 12, 75.0%), sleep disturbance (n = 9, 56.3%), and impact on work (n = 9, 56.3%) were the most commonly reported. For CD, the QUALMS and FACT-An were found to be mostly relevant and very well understood; response options were easy to use, and recall period was appropriate. Conclusion Both QUALMS and FACT-An demonstrated a strong face and content validity in patients with lower-risk MDS, suggesting that these instruments are appropriate for assessing HRQoL in this population.
topic Myelodysplastic syndrome
Patient reported outcomes
FACT-An
QUALMS
Health-related quality of life
url http://link.springer.com/article/10.1186/s41687-020-00235-4
work_keys_str_mv AT jeremiahjtrudeau contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT jianminghe contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT estherrose contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT charlottepanter contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT sharanrandhawa contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT adamgater contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
_version_ 1724496973196689408